Compare IHT & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | BOLT |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 10.5M |
| IPO Year | 1995 | 2021 |
| Metric | IHT | BOLT |
|---|---|---|
| Price | $1.25 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 7.7K | ★ 14.8K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,600,000.00 | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | 0.07 |
| 52 Week Low | $0.95 | $0.26 |
| 52 Week High | $4.24 | $7.35 |
| Indicator | IHT | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 72.26 | 61.25 |
| Support Level | $0.97 | $5.24 |
| Resistance Level | $1.27 | $6.12 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 96.55 | 75.17 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.